The Chemours Company (CC) 10-Q 9 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 02, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	1,627,223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		181,470,350

Interim Consolidated Statements

Interim Consolidated Statements of Income (Unaudited) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net sales		$ 1,297	$ 1,363
Cost of goods sold		1,095	1,111
Gross profit		202	252
Selling, general and administrative expense		133	167
Research and development expense		23	23
Employee separation and asset related charges, net		17	0
Total expenses		173	190
Equity in earnings of affiliates		5	3
Interest expense, net		(57)	0
Other income (expense), net		93	(7)
Income before income taxes		70	58
Provision for income taxes		19	15
Net income		51	43
Less: Net income attributable to noncontrolling interests		0	0
Net income attributable to Chemours		$ 51	$ 43
Per share data
Basic earnings per share of common stock (USD per share)	[1]	$ 0.28	$ 0.24
Diluted earnings per share of common stock (USD per share)	[1]	0.28	0.24
Dividends per share of common stock (USD per share)		$ 0.02755496375000000	$ 0
[1]	On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings per common share for the three months ended March 31, 2015 were calculated using the number of shares distributed on July 1, 2015. Refer to Note 8 for information regarding the calculation of basic and diluted earnings per share.

Interim Consolidated Statement3

Interim Consolidated Statements of Income (Unaudited) (Parenthetical)	Jul. 01, 2015shares
Income Statement [Abstract]
Stock issued, common stock	180,966,833

Interim Consolidated Statement4

Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net (loss) Income, pre-tax	$ 70	$ 58
Net (loss) Income, tax	(19)	(15)
Net income	51	43
Other comprehensive income (loss):
Unrealized loss on net investment hedge, pre-tax	(7)	0
Unrealized loss on net investment hedge, tax	0	0
Unrealized loss on net investment hedge, after-tax	(7)	0
Cumulative translation adjustments, pre-tax	19	(206)
Cumulative translation adjustment, tax	0	0
Cumulative translation adjustment, after-tax	19	(206)
Pension benefit plans, net:
Net gain (loss), pre-tax	0	3
Net gain (loss), tax	0	(1)
Net gain (loss), after-tax	0	2
Effect of foreign exchange rates, pre-tax	(5)	32
Effect of foreign exchange rates, tax	1	(8)
Effect of foreign exchange rates, after-tax	(4)	24
Reclassifications to net income:
Amortization of prior service cost, pre-tax	0	1
Amortization of prior service cost, tax	0	0
Amortization of prior service cost, after tax	0	1
Amortization of loss, pre-tax	4	4
Amortization of loss, tax	(1)	(1)
Amortization of loss, after tax	3	3
Pension benefit plans, net, pre-tax	(1)	40
Pension benefit plans, net, tax	0	(10)
Pension benefit plans, net, after-tax	(1)	30
Other comprehensive loss, pre-tax	11	(166)
Other comprehensive loss, tax	0	(10)
Other comprehensive loss, after-tax	11	(176)
Comprehensive (loss) income, pre-tax	81	(108)
Comprehensive (loss) income, tax	(19)	(25)
Comprehensive (loss) income, after-tax	62	(133)
Comprehensive income (loss) attributable to noncontrolling Interests, pre-tax	0	0
Comprehensive income (loss) attributable to noncontrolling Interests, tax	0	0
Comprehensive income (loss) attributable to noncontrolling Interests, after-tax	0	0
Comprehensive (loss) income attributable to Chemours, pre-tax	81	(108)
Comprehensive (loss) income attributable to Chemours, tax	(19)	(25)
Comprehensive (loss) income attributable to Chemours, after-tax	$ 62	$ (133)

Interim Consolidated Balance Sh

Interim Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Assets
Cash	$ 435	$ 366
Accounts and notes receivable - trade, net	906	859
Inventories	948	972
Prepaid expenses and other	82	104
Total current assets	2,371	2,301
Property, plant and equipment	9,092	9,015
Less: Accumulated depreciation	(5,893)	(5,838)
Net property, plant and equipment	3,199	3,177
Goodwill	165	166
Other intangible assets, net	10	10
Investments in affiliates	144	136
Other assets	491	508
Total assets	6,380	6,298
Liabilities [Abstract]
Accounts payable	842	973
Short-term borrowings and current maturities of long-term debt	34	39
Other accrued liabilities	611	454
Total current liabilities	1,487	1,466
Long-term debt, net	3,920	3,915
Deferred income taxes	239	234
Other liabilities	542	553
Total liabilities	$ 6,188	$ 6,168
Commitments and contingent liabilities
Equity
Common stock (par value $.01 per share; 810,000,000 shares authorized; 181,460,309 shares issued and outstanding as of March 31, 2016)	$ 2	$ 2
Additional paid-in capital	775	775
Accumulated deficit	(64)	(115)
Accumulated other comprehensive loss	(525)	(536)
Total Chemours stockholders' equity	188	126
Noncontrolling interests	4	4
Total equity	192	130
Total liabilities and equity	$ 6,380	$ 6,298

Interim Consolidated Balance S6

Interim Consolidated Balance Sheet (Parenthetical)	Mar. 31, 2016$ / sharesshares
Statement of Financial Position [Abstract]
Common stock , par value (USD per share) | $ / shares	$ 0.01
Common stock, shares authorized	810,000,000
Common stock, shares issued	181,460,309
Common stock, shares outstanding	181,460,309

Interim Consolidated Statement7

Interim Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock [Member]	DuPont Company Net Investment [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Shares, beginning balance at Dec. 31, 2014		0
Total stockholders' equity, beginning balance at Dec. 31, 2014	$ 3,673	$ 0	$ 3,650	$ 0	$ 19	$ 0	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	43		43
Establishment of pension plans, net and related accumulated other comprehensive income (loss)	110		357		(247)
Other comprehensive income (loss)	(176)				(176)
Net transfers from DuPont	479		479
Shares, ending balance at Mar. 31, 2015		0
Total stockholders' equity, ending balance at Mar. 31, 2015	4,129	$ 0	4,529	0	(404)	0	4
Shares, beginning balance at Dec. 31, 2015		181,069,751
Total stockholders' equity, beginning balance at Dec. 31, 2015	130	$ 2	0	775	(536)	(115)	4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	51					51
Common stock issued - compensation plans (in shares)		390,558
Dividends	(5)			(5)
Other comprehensive income (loss)	11				11
Stock based compensation	5			5
Shares, ending balance at Mar. 31, 2016		181,460,309
Total stockholders' equity, ending balance at Mar. 31, 2016	$ 192	$ 2	$ 0	$ 775	$ (525)	$ (64)	$ 4

Interim Consolidated Statement8

Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net income	$ 51	$ 43
Adjustments to reconcile net income to cash provided by (used for) operating activities:
Depreciation and amortization	66	64
Amortization of debt issuance costs and discount	8	0
Gain on sale of assets and business	(89)	0
Equity in earnings of affiliates	(5)	(3)
Deferred tax expense	10	11
Other operating charges, net	55	11
Accounts and notes receivable - trade, net	(40)	(98)
Inventories and other operating assets	18	(88)
Accounts payable and other operating liabilities	(38)	(178)
Cash provided by (used for) operating activities	36	(238)
Investing activities
Purchases of property, plant and equipment	(89)	(137)
Proceeds from sales of assets and business	140	8
Foreign exchange contract settlements	(1)	0
Investment in affiliates	0	(30)
Cash provided by (used for) investing activities	50	(159)
Financing activities
Debt repayments	(9)	0
Deferred financing fees	(2)	0
Dividends paid	(5)	0
Net transfers from DuPont	0	397
Cash (used for) provided by financing activities	(16)	397
Effect of exchange rate changes on cash	(1)	0
Increase in cash	69	0
Cash at beginning of period	366	0
Cash at end of period	435	0
Non-cash investing activities:
Change in property, plant and equipment included in accounts payable	$ 3	$ 0

Background and Description of t

Background and Description of the Business	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Description of the Business	Background and Description of the Business The Chemours Company (Chemours or the Company) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO 2 ), refrigerants, industrial fluoropolymer resins, sodium cyanide and sulfuric acid. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom and France. As of March 31, 2016 , Chemours consists of 34 production facilities globally, five dedicated to Titanium Technologies, 16 dedicated to Fluoroproducts, 12 dedicated to Chemical Solutions and one that supports the Fluoroproducts and Chemical Solutions segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01 ) to holders of DuPont common stock (par value $0.30 ) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The separation was completed pursuant to a Separation Agreement and other agreements with DuPont related to the separation, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement. These agreements govern the relationship between Chemours and DuPont following the separation and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information. In the opinion of management, all adjustments considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. The year-end consolidated balance sheet does not include all disclosures required by accounting principles generally accepted in the United States of America. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise stated, references to years and three month periods relate to Chemours' fiscal years and three month periods. Certain reclassifications of prior year's data have been made to conform to current period presentation. Chemours did not operate as a separate, stand-alone entity for the full period covered by the 2015 interim consolidated financial statements. Prior to our separation on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the interim consolidated financial statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the interim consolidated financial statements. The interim consolidated financial statements include the historical operations, assets and liabilities of the legal entities that were considered to comprise the Chemours business, including certain environmental remediation and litigation obligations for which Chemours has indemnified DuPont. All of the allocations and estimates in the interim consolidated financial statements prior to July 1, 2015 were based on assumptions that management believes are reasonable. However, the interim consolidated financial statements for the three months ended March 31, 2015 included herein may not be indicative of the results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont in the Interim Consolidated Statements of Equity for the three months ended March 31, 2015 include a non-cash contribution from DuPont of $82 . This non-cash contribution occurred during physical separation activities at shared production facilities in the United States prior to the separation.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, "Compensation - Stock Compensation (Topic 718)." The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal period, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted for any entity in any interim or annual period. Chemours is currently evaluating the impact of adopting this guidance and does not expect the adoption will have a significant impact on its financial position or results of operations. In March 2016, the FASB issued ASU No. 2016-08, "Revenue from contracts with customers (Topic 606): Principal versus agent considerations (reporting revenue gross versus net)." The amendment clarifies the implementation guidance on principal versus agent considerations and affects the guidance in ASU 2014-09. This amendment is effective on the same effective date of ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a one year deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard while adoption as of the original effective date is also permitted. Chemours is currently evaluating the impact of adopting these guidance will have on its financial positions and results of operations. Also, in March 2016, the FASB issued ASU 2016-07, "Investments—Equity Method and Joint Ventures (Topic 323)." The amendments eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. Further, in March 2016, the FASB issued ASU 2016-06, "Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments," which clarifies Topic 815 requirements for assessing whether contingent call and/or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call and/or put options solely in accordance with the four-step decision sequence. The amendments in this update are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years, and the entity should apply the amendments on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements , and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance will have to its financial position, results of operations and debt covenants. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption did not have a significant effect on our financial position or results of operations. In April 2015, the FASB issued ASU 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no effect on our financial position, results of operations and cash flows. In June 2014, the FASB issued ASU No. 2014-12, "Compensation-Stock Compensation (Topic 718)," which requires an entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition in accordance with existing guidance in Topic 718. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance, effective January 1, 2016, prospectively to all awards granted or modified after the effective date. The adoption did not have a significant effect on our financial position and results of operations.

Relationship with DuPont and Re

Relationship with DuPont and Related Entities	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Relationship with DuPont and Related Entities	Relationship with DuPont and Related Entities Prior to the separation, including the three months ended March 31, 2015, Chemours sold finished goods to DuPont and its non-Chemours businesses. Related party sales to DuPont for the three months period ended March 31, 2015 were $1 , $18 and $10 recorded by Titanium Technologies, Fluoroproducts and Chemical Solutions, respectively. Subsequent to the separation, beginning on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Also prior to the separation, DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support. A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other. The allocated leveraged functional service expenses and general corporate expenses included in the Interim Consolidated Statements of Operations were $122 for the three months ended March 31, 2015 , and were recorded within cost of goods sold, selling, general and administrative expense and research and development expense for $13 , $105 and $4 , respectively. Subsequent to the separation on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Accordingly, no costs from DuPont were allocated to Chemours for the three months ended March 31, 2016 . Cash Management and Financing The separation agreements set forth a process to true-up cash and working capital transferred to us from DuPont at separation. In January 2016, Chemours and DuPont entered into an agreement, contingent upon the credit agreement amendment (described in Note 14), which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreements. As a result, Chemours was not required to make any payments to DuPont, nor did DuPont make any payments to Chemours. In addition, the agreement set forth an advance payment by DuPont of approximately $190 , which Chemours received in February 2016, for certain specified goods and services that Chemours expects to provide to DuPont over twelve to fifteen months under existing agreements between the parties. The advance payment was recorded as deferred liability included in other accrued liabilities of the Consolidated Balance Sheet and approximately $166 remain outstanding as of March 31, 2016 . Tax Matters Agreement Chemours and DuPont entered into a tax matters agreement that governs the parties’ respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state and local taxes (and any related interest, penalties or audit adjustments) reportable on a consolidated, combined or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the date of the separation and Chemours is responsible for any U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the date of the separation.

Employee Separation and Asset R

Employee Separation and Asset Related Charges, Net	3 Months Ended
	Mar. 31, 2016
Restructuring Charges [Abstract]
Employee Separation and Asset Related Charges, Net	Employee Separation and Asset Related Charges, Net For the three months ended March 31, 2016, Chemours recorded charges for employee separation and other restructuring related charges as follows: Three months ended March 31, 2016 2015 Employee separation charges $ 4 $ — Decommissioning and other charges 13 — Total $ 17 $ — The charges impacted segment earnings for the three months ended March 31, 2016 as follows: Titanium Technologies Fluoroproducts Chemical Solutions Total Plant and product line closures $ 8 $ 4 $ 1 $ 13 2015 Global restructuring 2 2 — 4 Total $ 10 $ 6 $ 1 $ 17 As a result of the decommissioning and dismantling activities due to the closure of the Edge Moor manufacturing plant in the U.S., for the three months ended March 31, 2016, the Company recorded charges of approximately $8 in the Titanium Technology segment. The decommissioning, dismantling and removal activities will continue for the remainder of 2016 through early 2017 and the Company expects to incur additional charges of approximately $40 , which will be expensed as incurred. The Company's Fluoroproducts segment also recorded charges of approximately $4 related to decommissioning, dismantling and removal activities on certain of its production lines in the U.S. The Company also expects to incur additional $5 for dismantling and removal costs in the remainder of 2016 through early 2017, which will be expensed as incurred. Further, following the announcement of a global workforce reduction in November 2015, the Company incurred an additional $4 of employee separation costs due to continued efforts to streamline and simplify its organizational structure and reduce costs. The following table shows the change in the employee separation related liability account associated with the restructuring programs: Titanium Technologies Site Closures Fluoroproducts Lines Shutdown Chemical Solutions Site Closures 2015 Global Restructuring Total Balance as of December 31, 2015 $ 11 $ 2 $ 12 $ 73 $ 98 Charges to income for the three months ended March 31, 2016 — — — 4 4 Charges to liability accounts: Payments (2 ) — — (18 ) (20 ) Net currency translation adjustment 1 — — — — — Balance as of March 31, 2016 $ 9 $ 2 $ 12 $ 59 $ 82 1 Net currency translation adjustment was less than $1 for all periods presented. There are no significant outstanding liabilities related to the decommissioning and other restructuring related charges.

Other Income (Expense), Net

Other Income (Expense), Net	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Other Income (Expense), Net	Other Income (Expense), Net Three months ended March 31, 2016 2015 Leasing, contract services and miscellaneous income 1 $ 7 $ 4 Royalty income 2 3 5 Gain on sale of assets and business 89 — Exchange losses, net 3 (6 ) (16 ) Total other income (expense), net $ 93 $ (7 ) 1 Miscellaneous income includes accrued interest related to unrecognized tax benefits. 2 Royalty income is primarily for technology and trademark licensing. 3 Exchange losses, net includes loss on derivative contracts of $1 and $11 for the three months ended March 31, 2016 and 2015 , respectively (see Note 16 for additional information). Dispositions In November 2015, the Company signed a definitive agreement to sell its aniline facility in Beaumont, Texas to The Dow Chemical Company (Dow), subject to customary approvals and closing conditions. The transaction closed on March 1, 2016 and Chemours received $140 in cash from Dow. The net book value of the asset disposed was $41 , which includes inventories, property, plant and equipment, other assets and allocated goodwill, and the Company incurred approximately $10 of transaction and other related charges. As a result, for the three months ended March 31, 2016, Chemours recognized a pre-tax gain of approximately $89 in the Chemical Solutions segment.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Chemours recorded a provision for income tax of $19 and $15 or an effective income tax rate of approximately 27% and 26% for the three months ended March 31, 2016 and 2015 , respectively. Each year, Chemours and/or its subsidiaries, file income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the tax matters agreement. As a result, income tax uncertainties are recognized in Chemours’ interim consolidated financial statements in accordance with accounting for income taxes, when applicable. It is reasonably possible that changes to Chemours' global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of such changes that may occur within the next twelve months cannot be made.

Earnings Per Share of Common St

Earnings Per Share of Common Stock	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share of Common Stock	Earnings Per Share of Common Stock The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated. Three months ended March 31, 2016 2015 Numerator: Net income attributable to Chemours $ 51 $ 43 Denominator: Weighted-average number of common shares outstanding - Basic 1 181,281,166 180,966,833 Dilutive effect of the company's employee compensation plans 2 221,974 — Weighted average number of common shares outstanding - Diluted 181,503,140 180,966,833 1 For March 31, 2015 , pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015. 2 Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect. The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation: Three months ended March 31, 2016 2015 Average number of stock options 8,701,474 —

Accounts and Notes Receivable -

Accounts and Notes Receivable - Trade, Net	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Accounts and Notes Receivable - Trade, Net	Accounts and Notes Receivable – Trade, Net March 31, 2016 December 31, 2015 Accounts receivable—trade, net 1 $ 816 $ 759 VAT, GST and other taxes 2 62 68 Leases receivable—current 12 13 Other receivables 3 16 19 Total $ 906 $ 859 1 Accounts receivable – trade, net includes trade notes receivable and is net of allowances of $ 5 and $ 4 as of March 31, 2016 and December 31, 2015 , respectively. Allowances are equal to the estimated uncollectible amounts. 2 Value Added Tax (VAT) and Goods and Services Tax (GST). 3 Other receivables consist of advances and other deposits. Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the three months ended March 31, 2016 . There was no bad debt expense for the three months ended March 31, 2015 .

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory, Net [Abstract]
Inventories	Inventories March 31, 2016 December 31, 2015 Finished products $ 645 $ 613 Semi-finished products 177 172 Raw materials, stores and supplies 371 433 Subtotal 1,193 1,218 Adjustment of inventories to a last-in, first-out (LIFO) basis (245 ) (246 ) Total $ 948 $ 972 Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the U.S. locations, which comprised $683 and $ 744 or 57% and 61% of inventories before the LIFO adjustments at March 31, 2016 and December 31, 2015 , respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment

Property, Plant, and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Depreciation expense amounted to $65 and $63 for the three months ended March 31, 2016 and 2015 , respectively. Property, plant and equipment includes gross assets under capital leases of $7 at March 31, 2016 and December 31, 2015 .

Other Intangible Assets, Net

Other Intangible Assets, Net	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets, Net	Other Intangible Assets, Net The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class: March 31, 2016 December 31, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer lists $ 13 $ (10 ) $ 3 $ 13 $ (10 ) $ 3 Patents 19 (17 ) 2 19 (17 ) 2 Purchased trademarks 5 (2 ) 3 5 (2 ) 3 Purchased and licensed technology 3 (1 ) 2 8 (6 ) 2 Total $ 40 $ (30 ) $ 10 $ 45 $ (35 ) $ 10 The aggregate amortization expense for definite-lived intangible assets was $1 for the three months ended March 31, 2016 and 2015 . Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from 5 to 20 years. There are no material indefinite-lived intangible assets. The estimated amortization for the remainder of 2016 and each of the succeeding four years is: Remainder of 2016 $ 2 2017 2 2018 1 2019 1 2020 1

Other Assets

Other Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	Other Assets March 31, 2016 December 31, 2015 Leases receivable - non-current $ 122 $ 125 Capitalized repair and maintenance costs 127 149 Pension assets 153 138 Deferred income taxes - non-current 39 47 Miscellaneous 1 50 49 Total $ 491 $ 508 1 Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $16 and $19 as of March 31, 2016 and December 31, 2015 , respectively. Direct Financing Leases At two of its facilities in the U.S. (Borderland and Morses Mill), Chemours has constructed fixed assets on land that it leases from third parties. Management has analyzed these arrangements and determined these assets represent a direct financing lease, whereby Chemours is the lessor of this equipment. Chemours has recorded leases receivable of $135 and $138 at March 31, 2016 and December 31, 2015 respectively, which represent the balance of the minimum future lease payments receivable. The current portion of leases receivable is included in accounts and notes receivable - trade, net, as shown in Note 9. The long-term portion of leases receivable are included in other assets, as shown above. The Company periodically evaluates the realizable value of these leased assets and determined no impairment existed at March 31, 2016 . There is no estimated future residual value of these leased assets.

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	Debt Long-term debt was comprised of the following at March 31, 2016 and December 31, 2015 : March 31, 2016 December 31, 2015 Long-term debt: Senior secured term loan $ 1,489 $ 1,493 Senior unsecured notes: 6.625%, due May 2023 1,350 1,350 7.00%, due May 2025 750 750 6.125%, due May 2023 (€360) 403 395 Other 20 26 Total 4,012 4,014 Less: Unamortized issue discount on senior secured term loan 6 7 Less: Unamortized debt issuance costs 52 53 Less: Current maturities 34 39 Total long-term debt $ 3,920 $ 3,915 Amendment to Senior Secured Credit Facilities During the first quarter of 2016, Chemours and its Revolving Credit Facility lenders entered into a second amendment to the credit agreement that (a) replaced the total net leverage ratio financial covenant with a senior secured net leverage ratio financial covenant; (b) reduced the minimum levels required by the interest expense coverage ratio covenant; (c) increased the limits and extended the period of adding back the benefits of announced cost reduction initiatives in the determination of Consolidated EBITDA for the purposes of calculating the financial maintenance covenants; and (d) reduced the revolver commitment from $1,000 to $750 . As a result of the amendment, the Company recorded a charge of approximately $4 to write off a proportionate amount of unamortized debt issuance costs attributable to the reduction in revolver commitment, which was included in interest expense, net. Fees and expenses of approximately $2 incurred in connection with the amendment were capitalized in other assets of the Consolidated Balance Sheet, which will be amortized to interest expense on a straight-line basis over the remaining term of the Revolving Credit Facility. The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants as of March 31, 2016 . Senior Unsecured Notes Chemours is required to register the senior unsecured notes (the Notes) with the SEC within 465 days after the original issue date under a registration rights arrangement. If Chemours fails to do so, it would be required to pay additional interest at a rate of 0.25 % for the first 90 days following a registration default and additional 0.25 % per annum with respect to each subsequent 90 -day period, up to a maximum rate of 0.50 %, until the registration requirements are met. During April 2016, the Company filed a registration statement on Form S-4 in connection with the registration rights arrangement. The Notes exchange offer commenced following the effectiveness of the registration statement and is expected to be completed in May 2016. While considered remote, the maximum potential consideration to be transferred should the Company fail to meet the registration rights requirement would be approximately $90 through the Notes maturity dates. Also, in May 2016, the Company's Euro Notes were admitted to listing on the Official List and trading on the Global Exchange Market of the Irish Stock Exchange. Maturities There are no debt maturities prior to year 2022, except, in accordance with the credit agreement, Chemours has required quarterly principal payments related to the Term Loan Facility equivalent to 1.00% per annum beginning September 2015 through March 2022, with the balance due at maturity. Term Loan principal maturities over the next five years are $11 for the remainder of 2016 and $15 in each year from 2017 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2022 and beyond will be $3,906 . In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, the Company is also required to make additional principal repayment to the term loan facility equivalent to 50% of excess cash flow based on certain leverage targets (as defined in the credit agreement) with stepdowns to 25% and 0% as actual leverage decreases. Debt Fair Value The fair values of the Term Loan Facility, the 2023 notes, the 2025 notes and the 2023 Euro notes at March 31, 2016 were approximately $1,420 , $1,095 , $596 and $319 , respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Commitments and Contingent Liabilities (a) Guarantees Chemours has directly guaranteed various obligations of customers, suppliers and other third parties. As of March 31, 2016 and December 31, 2015 , the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties is approximately $8 . No amounts were accrued at March 31, 2016 and December 31, 2015 . (b) Litigation In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to or required under the separation-related agreements executed prior to the Distribution to indemnify DuPont against various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter, these indemnification claims could materially adversely affect Chemours' financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours. Asbestos At March 31, 2016 , there were approximately 2,180 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside the U.S. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products. At March 31, 2016 and December 31, 2015 , Chemours had an accrual of $44 related to this matter. Chemours reviews this estimate and related assumptions quarterly and annually updates the results of an approximate 20 -year projection. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter. Benzene In the separation, DuPont assigned its Benzene docket to Chemours. There are 28 pending cases against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products, such as paints, thinners and reducers. A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood's Acute Myelogenous Leukemia (AML) was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the Plaintiffs favor awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company's motion, the Court struck the punitive award. Through DuPont, Chemours has filed a motion for new trial and, if denied, will appeal the remaining award based upon substantial errors made at the trial court. Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each Benzene matter is highly fact driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time. PFOA Prior to the fourth quarter of 2014, Chemours used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. Chemours had accruals of $20 related to the PFOA matters discussed below at March 31, 2016 and December 31, 2015 . The accruals include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection (NJDEP). These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory. Drinking Water Actions In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70 , which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol. In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $ 235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of March 31, 2016 , less than $1 has been disbursed from the escrow account related to medical monitoring. In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA) and private well users. Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At March 31, 2016 , there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia. These lawsuits are consolidated in multi-district litigation (MDL) in Ohio federal court. Based on the information currently available to the Company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 30 lawsuits alleging wrongful death. In the third quarter of 2014, six plaintiffs from the MDL were selected for individual trial. The first case (Bartlett v. DuPont) was tried to a verdict on October 7, 2015. The Plaintiff alleged that PFOA in drinking water caused her kidney cancer with causes of action for negligence and negligent infliction of emotional distress. The jury found in favor of the Plaintiff, awarding $1.1 in damages for negligence and $0.5 for emotional distress. The jury found that DuPont’s conduct did not warrant punitive damages. DuPont Management believes that rulings made before and during the trial resulted in several significant and meritorious grounds for appeal, and has filed an appeal to the Sixth Circuit. The second case (Wolf v. DuPont), set for trial in March 2016, has been settled for an amount well below the incremental cost of preparing for trial. There are three more trials scheduled in 2016, with the next trial starting in May 2016. The court announced that, starting in May 2017, 40 individual plaintiff trials will be scheduled per year. This multi-year plan pertains only to the cases claiming cancer, which represents approximately 7% of the total number of cases in the MDL. The remaining cases, comprising approximately 93% of the docket, will remain inactive. Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. Except for the Wolf v. DuPont case, no claims have been settled or resolved during the periods presented. PFOA Summary While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. Chemours believes that it is reasonably possible that it could incur losses related to the MDL in Ohio federal court discussed above but such losses cannot be estimated at this time due to the uniqueness of the individual MDL plaintiff's claims and Chemours' defenses to those claims, both as to potential liability and damages on an individual claim basis, and numerous unsettled legal issues, among other factors. The trials and appeals of these matters will occur over the course of many years. Significant unfavorable outcomes in a number of cases in the MDL could have a material adverse effect on Chemours' consolidated financial position, results of operations or liquidity. (c) Environmental Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3 to the consolidated financial statements in our Annual Report on Form 10-K. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities. At March 31, 2016 , the Interim Consolidated Balance Sheets included a liability of $293 , relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $600 above the amount accrued at March 31, 2016 . Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours. Pompton Lakes The environmental remediation accrual is $86 as of March 31, 2016 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that remediation activities at this site could range up to $119 including previously accrued amounts. This could have a material impact on the liquidity of Chemours in any given period if recognized. However, management does not believe this would have a material adverse effect on Chemours' overall financial condition, liquidity or results of operations. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site were ceased in the mid 1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds. Under the authority of the EPA and the NJDEP, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours, through DuPont, has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 over the next two to three years, which is included in the remediation accrual as of March 31, 2016, in connection with remediation activities at Pompton Lakes, including activities related to the EPA’s proposed plan. The Company expects these activities to begin sometime on or after mid-2016; however initiation of this work in the field is dependent upon timing of agency approval of permits and implementation plans.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments Derivative Instruments Foreign Currency Forward Contracts Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis on the balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the statements of operations during the period in which they occurred. At March 31, 2016 , there were 40 foreign currency forward contracts outstanding with an aggregate gross notional value of $ 270 . Chemours recognized losses of $1 and $11 for the three months ended March 31, 2016 and 2015, respectively, in other income, net in the Interim Consolidated Statements of Income. Net Investment Hedge - Foreign Currency Borrowings Beginning on July 1, 2015, Chemours designated its €360 Euro notes (see Note 14) as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours used the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro notes due to remeasurement of the effective portion is reported in accumulated other comprehensive income on the balance sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the statements of operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. For the three months ended March 31, 2016, Chemours did not record any ineffectiveness and recognized a loss of $7 on its net investment hedges in accumulated other comprehensive income (loss). Fair Value of Derivative Instruments The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy: Fair Value Using Level 2 Inputs Balance Sheet Location March 31, 2016 December 31, 2015 Asset derivatives: Foreign currency forward contracts Accounts and notes receivable - trade, net $ 1 $ 2 Total asset derivatives $ 1 $ 2 Liability derivatives Foreign currency forward contracts Other accrued liabilities $ 2 $ 2 Total liability derivatives $ 2 $ 2 We classify our foreign currency forward contracts as Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

Long-Term Employee Benefits

Long-Term Employee Benefits	3 Months Ended
	Mar. 31, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Long-Term Employee Benefits	Long-Term Employee Benefits The components of net periodic benefit cost (income) for all significant pension plans were as follows: Three months ended March 31, 2016 2015 Service cost $ 3 $ 3 Interest cost 5 5 Expected return on plan assets (16 ) (21 ) Amortization of loss 4 4 Amortization of prior service cost — 1 Net periodic benefit income $ (4 ) $ (8 ) The net periodic benefit income is based on estimated values and an extensive use of assumptions about the discount rate, expected return on plan assets and the rate of future compensation increases received by the Company’s employees. Chemours made cash contributions of $5 to its pension plans during the three months ended March 31, 2016, and expects to make additional cash contributions of $13 to the pension plan during the remainder of 2016. Participation in the DuPont Plans Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. benefit plans, except in the Netherlands and Taiwan, as though they were participants in a multi-employer plan with the other businesses of DuPont. As a result, for the three months ended March 31, 2015, Chemours recognized $27 of pension and other long-term benefit expenses allocated by DuPont based on Chemours' active employee headcount.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation	Stock-based Compensation Total stock-based compensation cost included in the Interim Consolidated Statements of Income was $5 and $2 for the three months ended March 31, 2016 and 2015 , respectively. The income tax benefits related to stock-based compensation arrangements were $2 and less than $1 for the three months ended March 31, 2016 and 2015 , respectively. Stock-based compensation expense in prior years and until separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours employees participated. Adopted at separation, the Chemours Equity and Incentive Plan grants certain employees, independent contractors, or non-employee directors of the Company different forms of awards, including stock options and restricted stock units (RSUs). The Equity and Incentive Plan has a maximum shares reserve of 13,500,000 for the grant of equity awards plus the number of shares of DuPont equity awards that converted into new Chemours equity awards. The Chemours Compensation Committee determines the long-term incentive mix, including stock options and RSUs, and may authorize new grants annually. As of March 31, 2016, 8,976,857 shares of the Equity and Incentive Plan are still available for grants. Subject to vesting conditions of the award, a retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date. Stock Options In the first quarter 2016, Chemours granted non-qualified options to certain of its employees, which will serially vest over a three -year period and expire 10 years from date of grant. The expense related to stock options granted in the three months ended March 31, 2016 was based on the assumptions shown in the table below. No stock options were granted by Chemours in the three months ended March 31, 2015. Assumptions Three Months Ended March 31, 2016 Risk-free interest rate 1.47 % Expected term (years) 6.00 Volatility 80.24 % Dividend yield 2.22 % Fair value per stock option $ 3.15 The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company's debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined using a simplified approach, calculated as the midpoint between the vesting period and the contractual life of the award. The following table summarizes Chemours stock option activity for the three months ended March 31, 2016 . Number of Shares (in thousands) Weighted Average Exercise Price(per share) Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2015 8,284 $ 14.66 4.82 $ — Granted 1,285 5.40 Exercised — — Forfeited (95 ) 17.45 Expired (356 ) 5.82 Outstanding, March 31, 2016 9,118 13.68 5.50 $ 2,055 Exercisable, March 31, 2016 5,595 13.68 3.80 $ — The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the company's closing stock price on the last trading day of March 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter end. The amount changes based on the fair market value of the company's stock. No options were exercised in the three months ended March 31, 2016 . As of March 31, 2016 , $4 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 1.67 years. RSUs In the first quarter 2016, Chemours granted additional RSUs to key senior management employees that generally vest over a three -year period and, upon vesting, convert one -for-one to Chemours common stock. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date. Non-vested awards of RSUs, both with and without a performance condition, as of March 31, 2016 are shown below. The weighted-average grant-date fair value of RSUs granted during the first quarter 2016 was $5.39 . Number of Shares (in thousands) Weighted Average Grant Date Fair Value (per share) Nonvested, December 31, 2015 2,349 14.87 Granted 779 5.39 Vested (540 ) 16.01 Forfeited (29 ) 14.95 Nonvested, March 31, 2016 2,559 11.82 As of March 31, 2016 , there was $23 of unrecognized stock-based compensation expense related to nonvested awards. That cost is expected to be recognized over a weighted-average period of 1.50 years. Performance Share Units In the first quarter 2016, Chemours issued performance share units (“PSU”) to key senior management employees, which upon vesting, covert one -for-one to Chemours' common stock if specified performance goals, including certain market-based conditions, are met over three year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against the performance goals. During the three months ended March 31, 2016, the Company recorded stock-based compensation related to PSUs as a component of selling, general and administrative expense of less than $1 . There were no PSUs granted prior to the first quarter of 2016 . The following table provides compensation costs for stock-based compensation related to PSUs. Number of Share Units (in thousands) Weighted Average Grant Date Fair Value (per share) Nonvested, December 31, 2015 — $ — Granted 734 6.10 Vested — — Forfeited — — Nonvested, March 31, 2016 734 $ 6.10 A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the three months ended March 31, 2016 was $6.10 . The fair value of each PSU grant is amortized monthly into compensation expense on a straight-line basis over their respective vesting periods over 36 months. The accrual of compensation costs is based on our estimate of the final expected value of the award, and is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal, and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of the PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	Segment Information Chemours’ operations are classified into three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution and regulatory environment. Chemours’ reportable segments are Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the reportable segments and foreign exchange gains and losses are reflected in Corporate and Other. Segment sales include transfers to another reportable segment. Adjusted EBITDA is the primary measure of segment profitability used by the Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes excluding the following: • interest expense, depreciation and amortization, • non-operating pension and other postretirement employee benefit costs, • exchange gains (losses), • employee separation, asset-related charges and other charges, net, • asset impairments, • gains (losses) on sale of business or assets, and • other items not considered indicative of our ongoing operational performance and expected to occur infrequently. The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA. Three months ended March 31, Titanium Technologies Fluoroproducts Chemical Solutions Corporate and Other Total 2016 Net sales $ 521 $ 531 $ 245 $ — $ 1,297 Adjusted EBITDA 54 85 10 (21 ) $ 128 Depreciation and amortization 22 24 11 9 66 2015 Net sales $ 545 $ 552 $ 266 $ — $ 1,363 Adjusted EBITDA 93 75 1 (24 ) 145 Depreciation and amortization 31 21 12 — 64 Total Adjusted EBITDA reconciles to consolidated income before income taxes as follows: Three months ended March 31, 2016 2015 Total Adjusted EBITDA $ 128 $ 145 Interest (57 ) — Depreciation and amortization (66 ) (64 ) Non-operating pension and other postretirement employee benefit costs 7 (7 ) Exchange losses (6 ) (16 ) Restructuring charges (17 ) — Transaction, legal and other charges (8 ) — Gain on sale of assets or business 89 — Income before income taxes 70 58 Provision for income taxes 19 15 Net income $ 51 $ 43

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 22, 2016, the Company entered into a stock and asset purchase agreement with LANXESS Corporation, (“Lanxess”), pursuant to which Lanxess has agreed to acquire Chemours’ Clean & Disinfect product line (the “C&D Business”) by acquiring certain Chemours' subsidiaries, including a guarantor subsidiary, and assets comprising the C&D business for a purchase price of $ 230 in cash, subject to customary working capital and other adjustments. The company expects to close the transaction and record a gain in the second half of 2016. The completion of the transaction is subject to certain customary closing conditions and regulatory approvals.

Guarantor Condensed Consolidati

Guarantor Condensed Consolidating Financial Information	3 Months Ended
	Mar. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Condensed Consolidating Financial Information	Guarantor Condensed Consolidating Financial Information In connection with the issuance of the Notes by The Chemours Company (the “Parent Issuer”), this guarantor financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, the “Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the “Non-Guarantor Subsidiaries”). The Guarantor Subsidiaries of the Notes, excluding the Parent Issuer, will be automatically released from those guarantees upon the occurrence of certain customary release provisions. The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10: • the Consolidating Statements of Comprehensive Income (Loss) for the three months ended March 31, 2016 and 2015 ; • the Consolidating Balance Sheets as of March 31, 2016 and December 31, 2015 ; and • the Consolidating Statements of Cash Flows for the three months ended March 31, 2016 and 2015 . As discussed in Note 2, Chemours did not operate as a separate, stand-alone entity for the full period covered by consolidated financial statements. Prior to our separation on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including, but not limited, to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. The accompanying condensed consolidated financial information for the three months ended March 31, 2015 have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. The condensed consolidating financial information are presented using the equity method of accounting for its investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the interim consolidated financial statements presented and other notes related thereto contained in this quarterly report. As discussed in Note 20, the Company entered into a stock and asset purchase agreement with Lanxess, pursuant to which Lanxess has agreed to acquire Chemours’ C&D Business by acquiring certain Chemours’ subsidiaries and assets comprising the C&D business, which include a guarantor subsidiary International Dioxcide, Inc. (“IDI”), a restricted subsidiary as defined in the indenture governing the notes. IDI will be automatically released from the guarantees pursuant to the provision of the indenture upon completion of the sale, which is expected to be completed in the second half of 2016. Condensed Consolidating Statements of Comprehensive (Loss) Income Three Months Ended March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Net sales $ — $ 981 $ 721 $ (405 ) $ 1,297 Cost of goods sold — 875 617 (397 ) 1,095 Gross profit — 106 104 (8 ) 202 Selling, general and administrative expense 7 98 33 (5 ) 133 Research and development expense — 22 1 — 23 Employee separation and asset related charges, net — 17 — — 17 Total expenses 7 137 34 (5 ) 173 Equity in earnings of affiliates — — 5 — 5 Equity in earnings of subsidiaries 78 — — (78 ) — Interest expense, net (56 ) (1 ) — — (57 ) Intercompany interest income (expense), net 15 1 (16 ) — — Other income (loss), net 5 99 (5 ) (6 ) 93 Income before income taxes 35 68 54 (87 ) 70 (Benefit from) provision for income taxes (16 ) 29 9 (3 ) 19 Net income 51 39 45 (84 ) 51 Less: Net income attributable to noncontrolling interests — — — — — Net income attributable to Chemours $ 51 $ 39 $ 45 $ (84 ) $ 51 Comprehensive income attributable to Chemours $ 62 $ 39 $ 63 $ (102 ) $ 62 Condensed Consolidating Statements of Comprehensive Income Three Months Ended March 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Net sales $ — $ 1,027 $ 761 $ (425 ) $ 1,363 Cost of goods sold — 892 653 (434 ) 1,111 Gross profit — 135 108 9 252 Selling, general and administrative expense — 109 58 — 167 Research and development expense — 23 — — 23 Total expenses — 132 58 — 190 Equity in earnings of affiliates — — 3 — 3 Equity in earnings of subsidiaries 43 — — (43 ) — Other expense, net — (2 ) (5 ) — (7 ) Income before income taxes 43 1 48 (34 ) 58 Provision for income taxes — — 15 — 15 Net income 43 1 33 (34 ) 43 Less: Net income attributable to noncontrolling interests — — — — — Net income attributable to Chemours $ 43 $ 1 $ 33 $ (34 ) $ 43 Comprehensive (loss) income attributable to Chemours $ (133 ) $ 1 $ (143 ) $ 142 $ (133 ) Condensed Consolidating Balance Sheets March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Assets Current assets: Cash $ — $ 175 $ 260 $ — $ 435 Accounts and notes receivable - trade, net — 416 490 — 906 Intercompany receivable 19 565 102 (686 ) — Inventories — 459 520 (31 ) 948 Prepaid expenses and other — 40 57 (15 ) 82 Total current assets 19 1,655 1,429 (732 ) 2,371 Property, plant and equipment — 7,104 1,988 — 9,092 Less: Accumulated depreciation — (4,937 ) (956 ) — (5,893 ) Net property, plant and equipment — 2,167 1,032 — 3,199 Goodwill — 141 24 — 165 Other intangible assets, net — 10 — — 10 Investments in affiliates — 9 135 — 144 Investment in subsidiaries 3,231 — — (3,231 ) — Intercompany notes receivable 1,150 — — (1,150 ) — Other assets 16 254 221 — 491 Total assets $ 4,416 $ 4,236 $ 2,841 $ (5,113 ) $ 6,380 Liabilities and equity Current liabilities: Accounts payable $ 1 $ 548 $ 293 $ — $ 842 Short-term borrowings and current maturities of long-term debt 15 19 — — 34 Intercompany payable 230 102 354 (686 ) — Other accrued liabilities 64 431 116 — 611 Total current liabilities 310 1,100 763 (686 ) 1,487 Long-term debt 3,918 2 — — 3,920 Intercompany notes payable — — 1,150 (1,150 ) — Deferred income taxes — 194 45 — 239 Other liabilities — 443 99 — 542 Total liabilities 4,228 1,739 2,057 (1,836 ) 6,188 Commitments and contingent liabilities Equity Total Chemours stockholders' equity 188 2,497 780 (3,277 ) 188 Noncontrolling interests — — 4 — 4 Total equity 188 2,497 784 (3,277 ) 192 Total liabilities and equity $ 4,416 $ 4,236 $ 2,841 $ (5,113 ) $ 6,380 Condensed Consolidating Balance Sheets December 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Assets Current assets: Cash $ — $ 95 $ 271 $ — $ 366 Accounts and notes receivable - trade, net — 344 515 — 859 Intercompany receivable 3 459 54 (516 ) — Inventories — 493 501 (22 ) 972 Prepaid expenses and other — 49 52 3 104 Total current assets 3 1,440 1,393 (535 ) 2,301 Property, plant and equipment — 7,070 1,945 — 9,015 Less: Accumulated depreciation — (4,899 ) (939 ) — (5,838 ) Net property, plant and equipment — 2,171 1,006 — 3,177 Goodwill — 141 25 — 166 Other intangible assets, net — 10 — — 10 Investments in affiliates — 9 127 — 136 Investments in subsidiaries 3,105 — — (3,105 ) — Intercompany notes receivable 1,150 — — (1,150 ) — Other assets 19 275 214 — 508 Total assets $ 4,277 $ 4,046 $ 2,765 $ (4,790 ) $ 6,298 Liabilities and equity Current liabilities: Accounts payable $ — $ 637 $ 336 $ — $ 973 Short-term borrowings and current maturities of long-term debt 15 24 — — 39 Intercompany payable 202 54 260 (516 ) — Other accrued liabilities 21 287 146 — 454 Total current liabilities 238 1,002 742 (516 ) 1,466 Long-term debt 3,913 2 — — 3,915 Intercompany notes payable — — 1,150 (1,150 ) — Deferred income taxes — 173 61 — 234 Other liabilities — 456 97 — 553 Total liabilities 4,151 1,633 2,050 (1,666 ) 6,168 Commitments and contingent liabilities Equity Total Chemours stockholders' equity 126 2,413 711 (3,124 ) 126 Noncontrolling interests — — 4 — 4 Total equity 126 2,413 715 (3,124 ) 130 Total liabilities and equity $ 4,277 $ 4,046 $ 2,765 $ (4,790 ) $ 6,298 Condensed Consolidating Statements of Cash Flows Three Months Ended March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Operating activities Cash (used for) provided by operating activities $ (17 ) $ 21 $ 32 $ — $ 36 Investing activities Purchases of property, plant and equipment — (47 ) (42 ) — (89 ) Proceeds from sales of assets, net — 140 — — 140 Foreign exchange contract settlements — (1 ) — — (1 ) Intercompany investing activities — (28 ) — 28 — Cash provided by (used for) investing activities — 64 (42 ) 28 50 Financing activities Intercompany short-term borrowings, net 28 — — (28 ) — Debt repayments (4 ) (5 ) — — (9 ) Dividends paid (5 ) — — — (5 ) Debt issuance costs (2 ) — — — (2 ) Cash provided by (used for) financing activities 17 (5 ) — (28 ) (16 ) Effect of exchange rate changes on cash — — (1 ) — (1 ) Increase in cash — 80 (11 ) — 69 Cash at beginning of period — 95 271 — 366 Cash at end of period $ — $ 175 $ 260 $ — $ 435 Three Months Ended March 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Operating activities Cash used for operating activities $ — $ (124 ) $ (119 ) $ 5 $ (238 ) Investing activities Purchases of property, plant and equipment — (85 ) (52 ) — (137 ) Proceeds from sales of assets, net — 6 2 — 8 Investment in affiliates — — (30 ) — (30 ) Cash used for investing activities — (79 ) (80 ) — (159 ) Financing activities Net transfers from DuPont — 203 199 (5 ) 397 Cash provided by financing activities — 203 199 (5 ) 397 Effect of exchange rate changes on cash — — — — — Increase in cash — — — — — Cash at beginning of period — — — — — Cash at end of period $ — $ — $ — $ — $ —

Recent Accounting Pronounceme30

Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09, "Compensation - Stock Compensation (Topic 718)." The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal period, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted for any entity in any interim or annual period. Chemours is currently evaluating the impact of adopting this guidance and does not expect the adoption will have a significant impact on its financial position or results of operations. In March 2016, the FASB issued ASU No. 2016-08, "Revenue from contracts with customers (Topic 606): Principal versus agent considerations (reporting revenue gross versus net)." The amendment clarifies the implementation guidance on principal versus agent considerations and affects the guidance in ASU 2014-09. This amendment is effective on the same effective date of ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a one year deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard while adoption as of the original effective date is also permitted. Chemours is currently evaluating the impact of adopting these guidance will have on its financial positions and results of operations. Also, in March 2016, the FASB issued ASU 2016-07, "Investments—Equity Method and Joint Ventures (Topic 323)." The amendments eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the adoption of the equity method. Earlier application is permitted. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. Further, in March 2016, the FASB issued ASU 2016-06, "Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments," which clarifies Topic 815 requirements for assessing whether contingent call and/or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this update is required to assess the embedded call and/or put options solely in accordance with the four-step decision sequence. The amendments in this update are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years, and the entity should apply the amendments on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. Adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements , and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance will have to its financial position, results of operations and debt covenants. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption did not have a significant effect on our financial position or results of operations. In April 2015, the FASB issued ASU 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no effect on our financial position, results of operations and cash flows. In June 2014, the FASB issued ASU No. 2014-12, "Compensation-Stock Compensation (Topic 718)," which requires an entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition in accordance with existing guidance in Topic 718. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance, effective January 1, 2016, prospectively to all awards granted or modified after the effective date. The adoption did not have a significant effect on our financial position and results of operations.

Employee Separation and Asset31

Employee Separation and Asset Related Charges, Net (Tables)	3 Months Ended
	Mar. 31, 2016
Restructuring Charges [Abstract]
Schedule of Restructuring Program	For the three months ended March 31, 2016, Chemours recorded charges for employee separation and other restructuring related charges as follows: Three months ended March 31, 2016 2015 Employee separation charges $ 4 $ — Decommissioning and other charges 13 — Total $ 17 $ —
Schedule of Restructuring Charges	The charges impacted segment earnings for the three months ended March 31, 2016 as follows: Titanium Technologies Fluoroproducts Chemical Solutions Total Plant and product line closures $ 8 $ 4 $ 1 $ 13 2015 Global restructuring 2 2 — 4 Total $ 10 $ 6 $ 1 $ 17 The following table shows the change in the employee separation related liability account associated with the restructuring programs: Titanium Technologies Site Closures Fluoroproducts Lines Shutdown Chemical Solutions Site Closures 2015 Global Restructuring Total Balance as of December 31, 2015 $ 11 $ 2 $ 12 $ 73 $ 98 Charges to income for the three months ended March 31, 2016 — — — 4 4 Charges to liability accounts: Payments (2 ) — — (18 ) (20 ) Net currency translation adjustment 1 — — — — — Balance as of March 31, 2016 $ 9 $ 2 $ 12 $ 59 $ 82 1 Net currency translation adjustment was less than $1 for all periods presented.

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Schedule of Other Income	Three months ended March 31, 2016 2015 Leasing, contract services and miscellaneous income 1 $ 7 $ 4 Royalty income 2 3 5 Gain on sale of assets and business 89 — Exchange losses, net 3 (6 ) (16 ) Total other income (expense), net $ 93 $ (7 ) 1 Miscellaneous income includes accrued interest related to unrecognized tax benefits. 2 Royalty income is primarily for technology and trademark licensing. 3 Exchange losses, net includes loss on derivative contracts of $1 and $11 for the three months ended March 31, 2016 and 2015 , respectively (see Note 16 for additional information).

Earnings Per Share of Common 33

Earnings Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated. Three months ended March 31, 2016 2015 Numerator: Net income attributable to Chemours $ 51 $ 43 Denominator: Weighted-average number of common shares outstanding - Basic 1 181,281,166 180,966,833 Dilutive effect of the company's employee compensation plans 2 221,974 — Weighted average number of common shares outstanding - Diluted 181,503,140 180,966,833 1 For March 31, 2015 , pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015. 2 Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation: Three months ended March 31, 2016 2015 Average number of stock options 8,701,474 —

Accounts and Notes Receivable34

Accounts and Notes Receivable - Trade, Net (Tables)	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	March 31, 2016 December 31, 2015 Accounts receivable—trade, net 1 $ 816 $ 759 VAT, GST and other taxes 2 62 68 Leases receivable—current 12 13 Other receivables 3 16 19 Total $ 906 $ 859 1 Accounts receivable – trade, net includes trade notes receivable and is net of allowances of $ 5 and $ 4 as of March 31, 2016 and December 31, 2015 , respectively. Allowances are equal to the estimated uncollectible amounts. 2 Value Added Tax (VAT) and Goods and Services Tax (GST). 3 Other receivables consist of advances and other deposits.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory, Net [Abstract]
Schedule of Inventories	March 31, 2016 December 31, 2015 Finished products $ 645 $ 613 Semi-finished products 177 172 Raw materials, stores and supplies 371 433 Subtotal 1,193 1,218 Adjustment of inventories to a last-in, first-out (LIFO) basis (245 ) (246 ) Total $ 948 $ 972

Other Intangible Assets, Net (T

Other Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class: March 31, 2016 December 31, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer lists $ 13 $ (10 ) $ 3 $ 13 $ (10 ) $ 3 Patents 19 (17 ) 2 19 (17 ) 2 Purchased trademarks 5 (2 ) 3 5 (2 ) 3 Purchased and licensed technology 3 (1 ) 2 8 (6 ) 2 Total $ 40 $ (30 ) $ 10 $ 45 $ (35 ) $ 10
Summary of Estimated Amortization Expense	The estimated amortization for the remainder of 2016 and each of the succeeding four years is: Remainder of 2016 $ 2 2017 2 2018 1 2019 1 2020 1

Other Assets (Tables)

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	March 31, 2016 December 31, 2015 Leases receivable - non-current $ 122 $ 125 Capitalized repair and maintenance costs 127 149 Pension assets 153 138 Deferred income taxes - non-current 39 47 Miscellaneous 1 50 49 Total $ 491 $ 508 1 Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $16 and $19 as of March 31, 2016 and December 31, 2015 , respectively.

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt was comprised of the following at March 31, 2016 and December 31, 2015 : March 31, 2016 December 31, 2015 Long-term debt: Senior secured term loan $ 1,489 $ 1,493 Senior unsecured notes: 6.625%, due May 2023 1,350 1,350 7.00%, due May 2025 750 750 6.125%, due May 2023 (€360) 403 395 Other 20 26 Total 4,012 4,014 Less: Unamortized issue discount on senior secured term loan 6 7 Less: Unamortized debt issuance costs 52 53 Less: Current maturities 34 39 Total long-term debt $ 3,920 $ 3,915

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy: Fair Value Using Level 2 Inputs Balance Sheet Location March 31, 2016 December 31, 2015 Asset derivatives: Foreign currency forward contracts Accounts and notes receivable - trade, net $ 1 $ 2 Total asset derivatives $ 1 $ 2 Liability derivatives Foreign currency forward contracts Other accrued liabilities $ 2 $ 2 Total liability derivatives $ 2 $ 2
Schedule of Derivative Liabilities at Fair Value	The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy: Fair Value Using Level 2 Inputs Balance Sheet Location March 31, 2016 December 31, 2015 Asset derivatives: Foreign currency forward contracts Accounts and notes receivable - trade, net $ 1 $ 2 Total asset derivatives $ 1 $ 2 Liability derivatives Foreign currency forward contracts Other accrued liabilities $ 2 $ 2 Total liability derivatives $ 2 $ 2

Long-Term Employee Benefits (Ta

Long-Term Employee Benefits (Tables)	3 Months Ended
	Mar. 31, 2016
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Schedules of Net Periodic Benefit Cost (Income)	The components of net periodic benefit cost (income) for all significant pension plans were as follows: Three months ended March 31, 2016 2015 Service cost $ 3 $ 3 Interest cost 5 5 Expected return on plan assets (16 ) (21 ) Amortization of loss 4 4 Amortization of prior service cost — 1 Net periodic benefit income $ (4 ) $ (8 )

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Options Valuation Assumptions	The expense related to stock options granted in the three months ended March 31, 2016 was based on the assumptions shown in the table below. No stock options were granted by Chemours in the three months ended March 31, 2015. Assumptions Three Months Ended March 31, 2016 Risk-free interest rate 1.47 % Expected term (years) 6.00 Volatility 80.24 % Dividend yield 2.22 % Fair value per stock option $ 3.15
Schedule of Stock Options Activity	The following table summarizes Chemours stock option activity for the three months ended March 31, 2016 . Number of Shares (in thousands) Weighted Average Exercise Price(per share) Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Outstanding, December 31, 2015 8,284 $ 14.66 4.82 $ — Granted 1,285 5.40 Exercised — — Forfeited (95 ) 17.45 Expired (356 ) 5.82 Outstanding, March 31, 2016 9,118 13.68 5.50 $ 2,055 Exercisable, March 31, 2016 5,595 13.68 3.80 $ —
Schedule of Restricted Stock Units Activity	The weighted-average grant-date fair value of RSUs granted during the first quarter 2016 was $5.39 . Number of Shares (in thousands) Weighted Average Grant Date Fair Value (per share) Nonvested, December 31, 2015 2,349 14.87 Granted 779 5.39 Vested (540 ) 16.01 Forfeited (29 ) 14.95 Nonvested, March 31, 2016 2,559 11.82
Schedule of Performance Share Units Activity	The following table provides compensation costs for stock-based compensation related to PSUs. Number of Share Units (in thousands) Weighted Average Grant Date Fair Value (per share) Nonvested, December 31, 2015 — $ — Granted 734 6.10 Vested — — Forfeited — — Nonvested, March 31, 2016 734 $ 6.10

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Information	The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA. Three months ended March 31, Titanium Technologies Fluoroproducts Chemical Solutions Corporate and Other Total 2016 Net sales $ 521 $ 531 $ 245 $ — $ 1,297 Adjusted EBITDA 54 85 10 (21 ) $ 128 Depreciation and amortization 22 24 11 9 66 2015 Net sales $ 545 $ 552 $ 266 $ — $ 1,363 Adjusted EBITDA 93 75 1 (24 ) 145 Depreciation and amortization 31 21 12 — 64
Reconciliation of EBITDA from Segments to Consolidated	Total Adjusted EBITDA reconciles to consolidated income before income taxes as follows: Three months ended March 31, 2016 2015 Total Adjusted EBITDA $ 128 $ 145 Interest (57 ) — Depreciation and amortization (66 ) (64 ) Non-operating pension and other postretirement employee benefit costs 7 (7 ) Exchange losses (6 ) (16 ) Restructuring charges (17 ) — Transaction, legal and other charges (8 ) — Gain on sale of assets or business 89 — Income before income taxes 70 58 Provision for income taxes 19 15 Net income $ 51 $ 43

Guarantor Condensed Consolida43

Guarantor Condensed Consolidating Financial Information (Tables)	3 Months Ended
	Mar. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Statements of Comprehensive (Loss) Income	Condensed Consolidating Statements of Comprehensive (Loss) Income Three Months Ended March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Net sales $ — $ 981 $ 721 $ (405 ) $ 1,297 Cost of goods sold — 875 617 (397 ) 1,095 Gross profit — 106 104 (8 ) 202 Selling, general and administrative expense 7 98 33 (5 ) 133 Research and development expense — 22 1 — 23 Employee separation and asset related charges, net — 17 — — 17 Total expenses 7 137 34 (5 ) 173 Equity in earnings of affiliates — — 5 — 5 Equity in earnings of subsidiaries 78 — — (78 ) — Interest expense, net (56 ) (1 ) — — (57 ) Intercompany interest income (expense), net 15 1 (16 ) — — Other income (loss), net 5 99 (5 ) (6 ) 93 Income before income taxes 35 68 54 (87 ) 70 (Benefit from) provision for income taxes (16 ) 29 9 (3 ) 19 Net income 51 39 45 (84 ) 51 Less: Net income attributable to noncontrolling interests — — — — — Net income attributable to Chemours $ 51 $ 39 $ 45 $ (84 ) $ 51 Comprehensive income attributable to Chemours $ 62 $ 39 $ 63 $ (102 ) $ 62 Condensed Consolidating Statements of Comprehensive Income Three Months Ended March 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Net sales $ — $ 1,027 $ 761 $ (425 ) $ 1,363 Cost of goods sold — 892 653 (434 ) 1,111 Gross profit — 135 108 9 252 Selling, general and administrative expense — 109 58 — 167 Research and development expense — 23 — — 23 Total expenses — 132 58 — 190 Equity in earnings of affiliates — — 3 — 3 Equity in earnings of subsidiaries 43 — — (43 ) — Other expense, net — (2 ) (5 ) — (7 ) Income before income taxes 43 1 48 (34 ) 58 Provision for income taxes — — 15 — 15 Net income 43 1 33 (34 ) 43 Less: Net income attributable to noncontrolling interests — — — — — Net income attributable to Chemours $ 43 $ 1 $ 33 $ (34 ) $ 43 Comprehensive (loss) income attributable to Chemours $ (133 ) $ 1 $ (143 ) $ 142 $ (133 )
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Assets Current assets: Cash $ — $ 175 $ 260 $ — $ 435 Accounts and notes receivable - trade, net — 416 490 — 906 Intercompany receivable 19 565 102 (686 ) — Inventories — 459 520 (31 ) 948 Prepaid expenses and other — 40 57 (15 ) 82 Total current assets 19 1,655 1,429 (732 ) 2,371 Property, plant and equipment — 7,104 1,988 — 9,092 Less: Accumulated depreciation — (4,937 ) (956 ) — (5,893 ) Net property, plant and equipment — 2,167 1,032 — 3,199 Goodwill — 141 24 — 165 Other intangible assets, net — 10 — — 10 Investments in affiliates — 9 135 — 144 Investment in subsidiaries 3,231 — — (3,231 ) — Intercompany notes receivable 1,150 — — (1,150 ) — Other assets 16 254 221 — 491 Total assets $ 4,416 $ 4,236 $ 2,841 $ (5,113 ) $ 6,380 Liabilities and equity Current liabilities: Accounts payable $ 1 $ 548 $ 293 $ — $ 842 Short-term borrowings and current maturities of long-term debt 15 19 — — 34 Intercompany payable 230 102 354 (686 ) — Other accrued liabilities 64 431 116 — 611 Total current liabilities 310 1,100 763 (686 ) 1,487 Long-term debt 3,918 2 — — 3,920 Intercompany notes payable — — 1,150 (1,150 ) — Deferred income taxes — 194 45 — 239 Other liabilities — 443 99 — 542 Total liabilities 4,228 1,739 2,057 (1,836 ) 6,188 Commitments and contingent liabilities Equity Total Chemours stockholders' equity 188 2,497 780 (3,277 ) 188 Noncontrolling interests — — 4 — 4 Total equity 188 2,497 784 (3,277 ) 192 Total liabilities and equity $ 4,416 $ 4,236 $ 2,841 $ (5,113 ) $ 6,380 Condensed Consolidating Balance Sheets December 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Assets Current assets: Cash $ — $ 95 $ 271 $ — $ 366 Accounts and notes receivable - trade, net — 344 515 — 859 Intercompany receivable 3 459 54 (516 ) — Inventories — 493 501 (22 ) 972 Prepaid expenses and other — 49 52 3 104 Total current assets 3 1,440 1,393 (535 ) 2,301 Property, plant and equipment — 7,070 1,945 — 9,015 Less: Accumulated depreciation — (4,899 ) (939 ) — (5,838 ) Net property, plant and equipment — 2,171 1,006 — 3,177 Goodwill — 141 25 — 166 Other intangible assets, net — 10 — — 10 Investments in affiliates — 9 127 — 136 Investments in subsidiaries 3,105 — — (3,105 ) — Intercompany notes receivable 1,150 — — (1,150 ) — Other assets 19 275 214 — 508 Total assets $ 4,277 $ 4,046 $ 2,765 $ (4,790 ) $ 6,298 Liabilities and equity Current liabilities: Accounts payable $ — $ 637 $ 336 $ — $ 973 Short-term borrowings and current maturities of long-term debt 15 24 — — 39 Intercompany payable 202 54 260 (516 ) — Other accrued liabilities 21 287 146 — 454 Total current liabilities 238 1,002 742 (516 ) 1,466 Long-term debt 3,913 2 — — 3,915 Intercompany notes payable — — 1,150 (1,150 ) — Deferred income taxes — 173 61 — 234 Other liabilities — 456 97 — 553 Total liabilities 4,151 1,633 2,050 (1,666 ) 6,168 Commitments and contingent liabilities Equity Total Chemours stockholders' equity 126 2,413 711 (3,124 ) 126 Noncontrolling interests — — 4 — 4 Total equity 126 2,413 715 (3,124 ) 130 Total liabilities and equity $ 4,277 $ 4,046 $ 2,765 $ (4,790 ) $ 6,298
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows Three Months Ended March 31, 2016 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Operating activities Cash (used for) provided by operating activities $ (17 ) $ 21 $ 32 $ — $ 36 Investing activities Purchases of property, plant and equipment — (47 ) (42 ) — (89 ) Proceeds from sales of assets, net — 140 — — 140 Foreign exchange contract settlements — (1 ) — — (1 ) Intercompany investing activities — (28 ) — 28 — Cash provided by (used for) investing activities — 64 (42 ) 28 50 Financing activities Intercompany short-term borrowings, net 28 — — (28 ) — Debt repayments (4 ) (5 ) — — (9 ) Dividends paid (5 ) — — — (5 ) Debt issuance costs (2 ) — — — (2 ) Cash provided by (used for) financing activities 17 (5 ) — (28 ) (16 ) Effect of exchange rate changes on cash — — (1 ) — (1 ) Increase in cash — 80 (11 ) — 69 Cash at beginning of period — 95 271 — 366 Cash at end of period $ — $ 175 $ 260 $ — $ 435 Three Months Ended March 31, 2015 Parent Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations and Adjustments Consolidated Operating activities Cash used for operating activities $ — $ (124 ) $ (119 ) $ 5 $ (238 ) Investing activities Purchases of property, plant and equipment — (85 ) (52 ) — (137 ) Proceeds from sales of assets, net — 6 2 — 8 Investment in affiliates — — (30 ) — (30 ) Cash used for investing activities — (79 ) (80 ) — (159 ) Financing activities Net transfers from DuPont — 203 199 (5 ) 397 Cash provided by financing activities — 203 199 (5 ) 397 Effect of exchange rate changes on cash — — — — — Increase in cash — — — — — Cash at beginning of period — — — — — Cash at end of period $ — $ — $ — $ — $ —

Background and Description of44

Background and Description of the Business (Narrative) (Details)	Jul. 01, 2015	Mar. 31, 2016facilitysegment$ / shares	Jun. 23, 2015$ / shares
Segment Reporting Information [Line Items]
Number of reportable segments | segment		3
Number of facilities		34
Common stock , par value (USD per share) | $ / shares		$ 0.01	$ 0.01
Spin off transaction distribution ratio	0.2
Parent Company [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) | $ / shares			$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		1
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		16
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		12

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Millions	3 Months Ended
	Mar. 31, 2015USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Noncash contribution	$ 82

Relationship with DuPont and 46

Relationship with DuPont and Related Entities (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2016	Mar. 31, 2016	Mar. 31, 2015
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		$ 0	$ 122
Cost of Goods [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			13
Selling, General and Administrative Expenses [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			105
Research and Development Expense [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party			4
Titanium Technologies [Member] | Operating Segments [Member] | Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			1
Fluoroproducts [Member] | Operating Segments [Member] | Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			18
Chemical Solutions [Member] | Operating Segments [Member] | Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales			$ 10
Arrangement to Purchase Services and Materials [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Amount of agreement with related party	$ 190
Arrangement to Purchase Services and Materials [Member] | Minimum [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Remaining agreement term	12 months
Arrangement to Purchase Services and Materials [Member] | Maximum [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Remaining agreement term	15 months
Other Accrued Liabilities [Member] | Arrangement to Purchase Services and Materials [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
Deferred liability		$ 166

Employee Separation and Asset47

Employee Separation and Asset Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Employee separation charges	$ 4	$ 0
Decommissioning and other charges	13	0
Employee separation and asset related charges, net	$ 17	$ 0

Employee Separation and Asset48

Employee Separation and Asset Related Charges, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		4 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 17	$ 0
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	4		$ 4
Titanium Technologies [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	10
Expected cost remaining	40		40
Titanium Technologies [Member] | Operating Segments [Member] | 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	2
Fluoroproducts [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	6
Expected cost remaining	5		$ 5
Fluoroproducts [Member] | Operating Segments [Member] | 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	2
Plant and product line closures [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	13
Plant and product line closures [Member] | Titanium Technologies [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	8
Plant and product line closures [Member] | Fluoroproducts [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 4

Employee Separation and Asset49

Employee Separation and Asset Related Charges, Net (Segment Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		4 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 17	$ 0
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	4		$ 4
Operating Segments [Member] | Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	10
Operating Segments [Member] | Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	6
Operating Segments [Member] | Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	1
Operating Segments [Member] | 2015 Restructuring Program [Member] | Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	2
Operating Segments [Member] | 2015 Restructuring Program [Member] | Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	2
Operating Segments [Member] | 2015 Restructuring Program [Member] | Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	0
Plant and product line closures [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	13
Plant and product line closures [Member] | Operating Segments [Member] | Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	8
Plant and product line closures [Member] | Operating Segments [Member] | Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	4
Plant and product line closures [Member] | Operating Segments [Member] | Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	$ 1

Employee Separation and Asset50

Employee Separation and Asset Related Charges, Net (Restructuring Program schedule) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	$ 98
Restructuring charges	4
Payments	(20)
Net currency translation adjustment	0
Restructuring reserve, ending balance	82
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	11
Restructuring charges	0
Payments	(2)
Net currency translation adjustment	0
Restructuring reserve, ending balance	9
Fluoroproducts Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	2
Restructuring charges	0
Payments	0
Net currency translation adjustment	0
Restructuring reserve, ending balance	2
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	12
Restructuring charges	0
Payments	0
Net currency translation adjustment	0
Restructuring reserve, ending balance	12
2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	73
Restructuring charges	4
Payments	(18)
Net currency translation adjustment	0
Restructuring reserve, ending balance	59
Maximum [Member]
Restructuring Reserve [Roll Forward]
Net currency translation adjustment	$ 1

Other Income (Expense), Net (Sc

Other Income (Expense), Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Other Income and Expenses [Abstract]
Leasing, contract services and miscellaneous income	$ 7	$ 4
Royalty income	3	5
Gain on sale of assets or business	89	0
Exchange losses, net	(6)	(16)
Total other income (expense), net	93	(7)
Loss on derivative	$ 1	$ 11

Other Income (Expense), Net (As

Other Income (Expense), Net (Asset Disposition) (Details) - USD ($) $ in Millions	Mar. 01, 2016	Mar. 31, 2016	Mar. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets		$ 140	$ 8
Disposal group disposed of by sale | Aniline Facility, Beaumont, Texas [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 140
Transaction and other related charges		10
Disposal group disposed of by sale | Aniline Facility, Beaumont, Texas [Member] | Aniline Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net property, plant and equipment	$ 41
Disposal group disposed of by sale | Aniline Facility, Beaumont, Texas [Member] | Chemical Solutions [Member] | Operating Segments [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets		$ 89

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ 19	$ 15
Effective income tax rate	27.00%	26.00%

Earnings Per Share of Common 54

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($) $ in Millions	Jul. 01, 2015	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income attributable to Chemours		$ 51	$ 43
Denominator:
Weighted-average number of common shares outstanding- Basic		181,281,166	180,966,833
Dilutive effect of the company's employee compensation plans		221,974	0
Weighted average number of common shares outstanding - Diluted		181,503,140	180,966,833
Stock issued, common stock	180,966,833

Earnings Per Share of Common 55

Earnings Per Share of Common Stock (Antidilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Average number of stock options	8,701,474	0

Accounts and Notes Receivable56

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Accounts receivable—trade, net	$ 816	$ 759
VAT, GST and other taxes	62	68
Leases receivable—current	12	13
Other receivables	16	19
Total	$ 906	$ 859

Accounts and Notes Receivable57

Accounts and Notes Receivable - Trade, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 5		$ 4
Bad debt expense (less than $1 for the three months ended March 31, 2016)	$ 1	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Finished products	$ 645	$ 613
Semi-finished products	177	172
Raw materials, stores and supplies	371	433
Subtotal	1,193	1,218
Adjustment of inventories to a last-in, first-out (LIFO) basis	(245)	(246)
Total	948	972
LIFO inventory amount	$ 683	$ 744
Percentage of LIFO inventory	57.00%	61.00%

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 65	$ 63
Capital leased assets	$ 7		$ 7

Other Intangible Assets, Net (S

Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	$ 40	$ 45
Finite-lived Intangible Assets, Accumulated Amortization	(30)	(35)
Finite-lived Intangible Assets, Net	10	10
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	13	13
Finite-lived Intangible Assets, Accumulated Amortization	(10)	(10)
Finite-lived Intangible Assets, Net	3	3
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	19	19
Finite-lived Intangible Assets, Accumulated Amortization	(17)	(17)
Finite-lived Intangible Assets, Net	2	2
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	5	5
Finite-lived Intangible Assets, Accumulated Amortization	(2)	(2)
Finite-lived Intangible Assets, Net	3	3
Purchased and Licensed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	3	8
Finite-lived Intangible Assets, Accumulated Amortization	(1)	(6)
Finite-lived Intangible Assets, Net	$ 2	$ 2

Other Intangible Assets, Net (N

Other Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 1	$ 1
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years

Other Intangible Assets, Net 62

Other Intangible Assets, Net (Summary of Amortization Expense by Maturity) (Details) $ in Millions	Mar. 31, 2016USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2016	$ 2
2,017	2
2,018	1
2,019	1
2,020	$ 1

Other Assets (Details)

Other Assets (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)facility	Dec. 31, 2015USD ($)
Other Assets [Abstract]
Leases receivable - non-current	$ 122	$ 125
Capitalized repair and maintenance costs	127	149
Pension assets	153	138
Deferred income taxes - non-current	39	47
Miscellaneous	50	49
Total	$ 491	508
Number of facilities with fixed assets constructed on land | facility	2
Leases receivable	$ 135	138
Estimated future residual value of leased assets	0
Revolving Credit Facility [Member]
Other Assets [Abstract]
Deferred financing fee	$ 16	$ 19

Debt (Components of Long-Term D

Debt (Components of Long-Term Debt) (Details) € in Millions, $ in Millions	Mar. 31, 2016USD ($)	Mar. 31, 2016EUR (€)	Dec. 31, 2015USD ($)	Dec. 31, 2015EUR (€)	Jul. 01, 2015EUR (€)
Debt Instrument [Line Items]
Long-term debt	$ 4,012		$ 4,014
Less: Unamortized issue discount on senior secured term loan	6		7
Less: Unamortized debt issuance costs	52		53
Less: Current maturities	34		39
Total long-term debt	3,920		3,915
Senior Notes [Member] | 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,350		$ 1,350
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Senior Notes [Member] | 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior Notes [Member] | 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 403		$ 395
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Long-term debt, gross | €		€ 360		€ 360	€ 360
Other [Member]
Debt Instrument [Line Items]
Long-term debt	$ 20		$ 26
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,489		$ 1,493
Debt instrument interest rate	1.00%	1.00%

Debt (Senior Secured Credit Fac

Debt (Senior Secured Credit Facilities) (Details) - Revolving Credit Facility [Member]	Jan. 01, 2019	Mar. 31, 2016USD ($)	Jun. 30, 2017	Dec. 31, 2016	Jan. 01, 2019	Jun. 30, 2017	Dec. 31, 2015USD ($)
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity		$ 750,000,000					$ 1,000,000,000
Write off of debt issuance costs		4,000,000
Other Assets [Member]
Line of Credit Facility [Line Items]
Capitalized debt costs		$ 2,000,000
Scenario, Forecast [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio	2		3	3.50
Semi-annual decrease in maximum net leverage ratio					0.25
Minimum interest coverage ratio	3					1.75
Semi-annual increase in minimum interest coverage ratio					0.25

Debt (Senior Unsecured Notes) (

Debt (Senior Unsecured Notes) (Details) - Senior Notes [Member] $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Debt Instrument [Line Items]
Debt Instrument, interest rate, additional	0.25%
Threshold consecutive days following registration default	90 days
Threshold consecutive days following registration default, additional	90 days
Debt Instrument, interest rate additional maximum	0.50%
Maximum potential consideration to be transferred	$ 90

Debt (Maturities and Fair Value

Debt (Maturities and Fair Value) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Senior Notes [Member] | 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%	6.625%
Senior Notes [Member] | 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%	7.00%
Senior Notes [Member] | 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%
Level 2 [Member] | Senior Notes [Member] | 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 1,095
Level 2 [Member] | Senior Notes [Member] | 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	596
Level 2 [Member] | Senior Notes [Member] | 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 319
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2,016	$ 11
2,017	15
2,018	15
2,019	15
2,020	15
2,021	15
2022 and beyond	$ 3,906
Covenant terms, additional principal prepayment. percentage of excess cash flow	50.00%
Covenant terms, additional principal prepayment. percentage of excess cash flow, stepdown level 1	25.00%
Covenant terms, additional principal prepayment. percentage of excess cash flow, stepdown level 2	0.00%
The Term Loan Facility [Member] | Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,420

Commitments and Contingent Li68

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Guarantee obligations	$ 8	$ 8

Commitments and Contingent Li69

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details) resident in Thousands	Oct. 20, 2015USD ($)	Oct. 07, 2015USD ($)	Sep. 30, 2014plantiff	May. 31, 2013doctor	Mar. 31, 2016USD ($)lawsuitwater_districtplantifftrial	Dec. 31, 2005USD ($)	Dec. 31, 2004resident	Dec. 31, 2015USD ($)	Jan. 31, 2012USD ($)
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements (less than $1)					$ 1,000,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed | lawsuit					2,180
Accrual balance					$ 44,000,000			$ 44,000,000
Annual review projection period					20 years
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness | lawsuit					28
Years of exposure to benzene	24 years
Compensatory damages awarded	$ 6,900,000
Punitive damages awarded	$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance					$ 20,000,000			$ 20,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size | resident							80
Number of doctors to release initial screening recommendations | doctor				3
Medical panel follow-up screening and diagnostic testing period			3 years
Number of water districts Company must provide treatment | water_district					6
Expected number of scheduled plaintiff trials annually | plantiff					40
Percentage of total cases in MDL claiming cancer					7.00%
Percentage of cases to remain active					93.00%
PFOA Matters: Drinking Water Actions [Member] | Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments						$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] | Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments						$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] | Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit									$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed | lawsuit					3,500
Lawsuits alleging wrongful death | lawsuit					30
PFOA MDL Plaintiffs selected for individual trial | plantiff			6
Damages awarded due to negligence		$ 1,100,000
Damages awarded due to emotional distress		$ 500,000
Number of remaining trials in fiscal year | trial					3
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss					$ 600,000,000
Maximum [Member] | PFOA Matters: Drinking Water Actions [Member] | Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss					$ 235,000,000

Commitments and Contingent Li70

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)	Jun. 30, 2015a
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 293,000,000
Pompton Lakes [Member] | Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	86,000,000
Area of lake | a		36
Environmental remediation expense	$ 50,000,000
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Minimum [Member] | Pompton Lakes [Member] | Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	2 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Loss contingency, potential additional loss	$ 600,000,000
Maximum [Member] | Pompton Lakes [Member] | Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	3 years
Loss contingency, potential additional loss	$ 119,000,000

Financial Instruments (Details)

Financial Instruments (Details) € in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)contract	Mar. 31, 2015USD ($)	Mar. 31, 2016EUR (€)contract	Dec. 31, 2015EUR (€)	Jul. 01, 2015EUR (€)
Derivative [Line Items]
Recognized loss on derivative net investment hedge, less than	$ 7
6.125% Due May 2023 [Member] | Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross | €			€ 360	€ 360	€ 360
Foreign Exchange Contract [Member]
Derivative [Line Items]
Number of forward exchange currency contracts | contract	40		40
Derivative notional value	$ 270
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | Other Income [Member]
Derivative [Line Items]
Derivative loss	$ 1	$ 11

Financial Instruments (Schedule

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Recurring [Member] - Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 1	$ 2
Liability derivatives	2	2
Foreign Exchange Contract [Member] | Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	1	2
Foreign Exchange Contract [Member] | Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 2	$ 2

Long-Term Employee Benefits (Sc

Long-Term Employee Benefits (Schedules of Net Periodic Benefit Cost) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 3	$ 3
Interest cost	5	5
Expected return on plan assets	(16)	(21)
Amortization of loss	4	4
Amortization of prior service cost	0	1
Net periodic benefit income	$ (4)	$ (8)

Long-Term Employee Benefits (Na

Long-Term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Pension and other long-term benefit expense		$ 27
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 5
Estimated future employer contributions in current fiscal year	$ 13

Stock-based Compensation (Detai

Stock-based Compensation (Details) - USD ($)	Jul. 01, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost		$ 5,000,000	$ 2,000,000
Income tax benefit (less than $1 for the period ended March 31, 2015)		$ 2,000,000	$ 1,000,000
Options granted during period (shares)			0
Options exercised during period (shares)		0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period		3 years
Expiration period		10 years
Options granted during period (shares)		1,285,000
Options exercised during period (shares)		0
Unrecognized compensation cost related to stock options		$ 4,000,000
Unrecognized compensation cost period for recognition		1 year 8 months
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period		3 years
Unrecognized compensation cost period for recognition		1 year 6 months
Weighted-average fair value at grant date (in dollars per share)		$ 5.39
Unrecognized compensation cost related to equity awards other than options		$ 23,000,000
Shares issued upon conversion of equity award		1
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost		$ 1,000,000
Stock-based compensation award vesting period		3 years
Weighted-average fair value at grant date (in dollars per share)		$ 6.10
Shares issued upon conversion of equity award		1
Minimum [Member] | Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant		0.00%
Maximum [Member] | Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant		200.00%
Chemours Company Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants	13,500,000	8,976,857
Requisite service period	6 months

Stock-based Compensation (Stock

Stock-based Compensation (Stock Option Assumptions) (Details) - Stock Option [Member]	3 Months Ended
	Mar. 31, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.47%
Expected term (years)	6 years
Volatility	80.24%
Dividend yield	2.22%
Fair value per stock option (in dollars per share)	$ 3.15

Stock-based Compensation (Sto77

Stock-based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Granted, shares		0
Exercised, shares	0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares	8,284,000
Granted, shares	1,285,000
Exercised, shares	0
Forfeited, shares	(95,000)
Expired, shares	(356,000)
Outstanding, ending balance, shares	9,118,000		8,284,000
Exercisable, shares	5,595,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 14.66
Granted, weighted average exercise price (in dollars per share)	5.40
Exercised, weighted average exercise price (in dollars per share)	0
Forfeited, weighted average exercise price (in dollars per share)	17.45
Expired, weighted average exercise price (in dollars per share)	5.82
Outstanding, weighted average exercise price, ending balance (in dollars per share)	13.68		$ 14.66
Exercisable, weighted average exercise price (in dollars per share)	$ 13.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	5 years 6 months		4 years 9 months 26 days
Options exercisable, weighted average remaining contractual term	3 years 9 months 18 days
Options outstanding, aggregate intrinsic value	$ 2,055		$ 0
Options exercisable, aggregate intrinsic value	$ 0

Stock-based Compensation (Restr

Stock-based Compensation (Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares | shares	2,349
Granted, shares | shares	779
Vested, shares | shares	(540)
Forfeited, shares | shares	(29)
Nonvested, ending balance, shares | shares	2,559
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares	$ 14.87
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	5.39
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	16.01
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	14.95
Nonvested, weighted average grant date fair value, ending balance (in dollars per share) | $ / shares	$ 11.82

Stock-based Compensation (Perfo

Stock-based Compensation (Performance Share Units) (Details) - Performance Share Units [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares | shares	0
Granted, shares | shares	734
Vested, shares | shares	0
Forfeited, shares | shares	0
Nonvested, ending balance, shares | shares	734
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares	$ 0
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	6.10
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	0
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	0
Nonvested, weighted average grant date fair value, ending balance (in dollars per share) | $ / shares	$ 6.10

Segment Information (Narrative)

Segment Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segment Information (Schedule o

Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net sales	$ 1,297	$ 1,363
Adjusted EBITDA	128	145
Depreciation and amortization	66	64
Corporate and Other [Member]
Net sales	0	0
Adjusted EBITDA	(21)	(24)
Depreciation and amortization	9	0
Titanium Technologies [Member] | Operating Segments [Member]
Net sales	521	545
Adjusted EBITDA	54	93
Depreciation and amortization	22	31
Fluoroproducts [Member] | Operating Segments [Member]
Net sales	531	552
Adjusted EBITDA	85	75
Depreciation and amortization	24	21
Chemical Solutions [Member] | Operating Segments [Member]
Net sales	245	266
Adjusted EBITDA	10	1
Depreciation and amortization	$ 11	$ 12

Segment Information (Reconcilia

Segment Information (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting [Abstract]
Total Adjusted EBITDA	$ 128	$ 145
Interest	(57)	0
Depreciation and amortization	(66)	(64)
Non-operating pension and other postretirement employee benefit costs	7	(7)
Exchange losses	(6)	(16)
Restructuring charges	(17)	0
Transaction, legal and other charges	(8)	0
Gain on sale of assets or business	89	0
Income before income taxes	70	58
Provision for income taxes	19	15
Net income	$ 51	$ 43

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Apr. 22, 2016USD ($)
Disposal group disposed of by sale | Clean and Disinfect Product Line [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase price	$ 230

Guarantor Condensed Consolida84

Guarantor Condensed Consolidating Financial Information - Statements of Comprehensive (Loss) Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Statement of Income Captions [Line Items]
Net sales	$ 1,297	$ 1,363
Cost of goods sold	1,095	1,111
Gross profit	202	252
Selling, general and administrative expense	133	167
Research and development expense	23	23
Employee separation and asset related charges, net	17	0
Total expenses	173	190
Equity in earnings of affiliates	5	3
Equity in earnings of subsidiaries	0	0
Interest expense, net	(57)	0
Intercompany interest income (expense), net	0
Other income (expense), net	93	(7)
Income before income taxes	70	58
Provision for income taxes	19	15
Net income	51	43
Less: Net income attributable to noncontrolling interests	0	0
Net income attributable to Chemours	51	43
Comprehensive income attributable to Chemours	62	(133)
Parent Company [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Cost of goods sold	0	0
Gross profit	0	0
Selling, general and administrative expense	7	0
Research and development expense	0	0
Employee separation and asset related charges, net	0
Total expenses	7	0
Equity in earnings of affiliates	0	0
Equity in earnings of subsidiaries	78	43
Interest expense, net	(56)
Intercompany interest income (expense), net	15
Other income (expense), net	5	0
Income before income taxes	35	43
Provision for income taxes	(16)	0
Net income	51	43
Less: Net income attributable to noncontrolling interests	0	0
Net income attributable to Chemours	51	43
Comprehensive income attributable to Chemours	$ 62	(133)
Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Ownership percentage	100.00%
Net sales	$ 981	1,027
Cost of goods sold	875	892
Gross profit	106	135
Selling, general and administrative expense	98	109
Research and development expense	22	23
Employee separation and asset related charges, net	17
Total expenses	137	132
Equity in earnings of affiliates	0	0
Equity in earnings of subsidiaries	0	0
Interest expense, net	(1)
Intercompany interest income (expense), net	1
Other income (expense), net	99	(2)
Income before income taxes	68	1
Provision for income taxes	29	0
Net income	39	1
Less: Net income attributable to noncontrolling interests	0	0
Net income attributable to Chemours	39	1
Comprehensive income attributable to Chemours	39	1
Non-Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	721	761
Cost of goods sold	617	653
Gross profit	104	108
Selling, general and administrative expense	33	58
Research and development expense	1	0
Employee separation and asset related charges, net	0
Total expenses	34	58
Equity in earnings of affiliates	5	3
Equity in earnings of subsidiaries	0	0
Interest expense, net	0
Intercompany interest income (expense), net	(16)
Other income (expense), net	(5)	(5)
Income before income taxes	54	48
Provision for income taxes	9	15
Net income	45	33
Less: Net income attributable to noncontrolling interests	0	0
Net income attributable to Chemours	45	33
Comprehensive income attributable to Chemours	63	(143)
Eliminations and Adjustments [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(405)	(425)
Cost of goods sold	(397)	(434)
Gross profit	(8)	9
Selling, general and administrative expense	(5)	0
Research and development expense	0	0
Employee separation and asset related charges, net	0
Total expenses	(5)	0
Equity in earnings of affiliates	0	0
Equity in earnings of subsidiaries	(78)	(43)
Interest expense, net	0
Intercompany interest income (expense), net	0
Other income (expense), net	(6)	0
Income before income taxes	(87)	(34)
Provision for income taxes	(3)	0
Net income	(84)	(34)
Less: Net income attributable to noncontrolling interests	0	0
Net income attributable to Chemours	(84)	(34)
Comprehensive income attributable to Chemours	$ (102)	$ 142

Guarantor Condensed Consolida85

Guarantor Condensed Consolidating Financial Information - Balance Sheets (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Assets
Cash	$ 435	$ 366
Accounts and notes receivable - trade, net	906	859
Intercompany receivable	0	0
Inventories	948	972
Prepaid expenses and other	82	104
Total current assets	2,371	2,301
Property, plant and equipment	9,092	9,015
Less: Accumulated depreciation	(5,893)	(5,838)
Net property, plant and equipment	3,199	3,177
Goodwill	165	166
Other intangible assets, net	10	10
Investments in affiliates	144	136
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	491	508
Total assets	6,380	6,298
Liabilities [Abstract]
Accounts payable	842	973
Short-term borrowings and current maturities of long-term debt	34	39
Intercompany payable	0	0
Other accrued liabilities	611	454
Total current liabilities	1,487	1,466
Long-term debt, net	3,920	3,915
Intercompany notes payable	0	0
Deferred income taxes	239	234
Other liabilities	542	553
Total liabilities	$ 6,188	$ 6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	$ 188	$ 126
Noncontrolling interests	4	4
Total equity	192	130	$ 4,129	$ 3,673
Total liabilities and equity	6,380	6,298
Eliminations and Adjustments [Member]
Assets
Cash	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	(686)	(516)
Inventories	(31)	(22)
Prepaid expenses and other	(15)	3
Total current assets	(732)	(535)
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Net property, plant and equipment	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	(3,231)	(3,105)
Intercompany notes receivable	(1,150)	(1,150)
Other assets	0	0
Total assets	(5,113)	(4,790)
Liabilities [Abstract]
Accounts payable	0	0
Short-term borrowings and current maturities of long-term debt	0	0
Intercompany payable	(686)	(516)
Other accrued liabilities	0	0
Total current liabilities	(686)	(516)
Long-term debt, net	0	0
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes	0	0
Other liabilities	0	0
Total liabilities	$ (1,836)	$ (1,666)
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	$ (3,277)	$ (3,124)
Noncontrolling interests	0	0
Total equity	(3,277)	(3,124)
Total liabilities and equity	(5,113)	(4,790)
Parent Company [Member]
Assets
Cash	0	0
Accounts and notes receivable - trade, net	0	0
Intercompany receivable	19	3
Inventories	0	0
Prepaid expenses and other	0	0
Total current assets	19	3
Property, plant and equipment	0	0
Less: Accumulated depreciation	0	0
Net property, plant and equipment	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in affiliates	0	0
Investment in subsidiaries	3,231	3,105
Intercompany notes receivable	1,150	1,150
Other assets	16	19
Total assets	4,416	4,277
Liabilities [Abstract]
Accounts payable	1	0
Short-term borrowings and current maturities of long-term debt	15	15
Intercompany payable	230	202
Other accrued liabilities	64	21
Total current liabilities	310	238
Long-term debt, net	3,918	3,913
Intercompany notes payable	0	0
Deferred income taxes	0	0
Other liabilities	0	0
Total liabilities	$ 4,228	$ 4,151
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	$ 188	$ 126
Noncontrolling interests	0	0
Total equity	188	126
Total liabilities and equity	4,416	4,277
Guarantor Subsidiaries [Member]
Assets
Cash	175	95
Accounts and notes receivable - trade, net	416	344
Intercompany receivable	565	459
Inventories	459	493
Prepaid expenses and other	40	49
Total current assets	1,655	1,440
Property, plant and equipment	7,104	7,070
Less: Accumulated depreciation	(4,937)	(4,899)
Net property, plant and equipment	2,167	2,171
Goodwill	141	141
Other intangible assets, net	10	10
Investments in affiliates	9	9
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	254	275
Total assets	4,236	4,046
Liabilities [Abstract]
Accounts payable	548	637
Short-term borrowings and current maturities of long-term debt	19	24
Intercompany payable	102	54
Other accrued liabilities	431	287
Total current liabilities	1,100	1,002
Long-term debt, net	2	2
Intercompany notes payable	0	0
Deferred income taxes	194	173
Other liabilities	443	456
Total liabilities	$ 1,739	$ 1,633
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	$ 2,497	$ 2,413
Noncontrolling interests	0	0
Total equity	2,497	2,413
Total liabilities and equity	4,236	4,046
Non-Guarantor Subsidiaries [Member]
Assets
Cash	260	271
Accounts and notes receivable - trade, net	490	515
Intercompany receivable	102	54
Inventories	520	501
Prepaid expenses and other	57	52
Total current assets	1,429	1,393
Property, plant and equipment	1,988	1,945
Less: Accumulated depreciation	(956)	(939)
Net property, plant and equipment	1,032	1,006
Goodwill	24	25
Other intangible assets, net	0	0
Investments in affiliates	135	127
Investment in subsidiaries	0	0
Intercompany notes receivable	0	0
Other assets	221	214
Total assets	2,841	2,765
Liabilities [Abstract]
Accounts payable	293	336
Short-term borrowings and current maturities of long-term debt	0	0
Intercompany payable	354	260
Other accrued liabilities	116	146
Total current liabilities	763	742
Long-term debt, net	0	0
Intercompany notes payable	1,150	1,150
Deferred income taxes	45	61
Other liabilities	99	97
Total liabilities	$ 2,057	$ 2,050
Commitments and contingent liabilities
Equity
Total Chemours stockholders' equity	$ 780	$ 711
Noncontrolling interests	4	4
Total equity	784	715
Total liabilities and equity	$ 2,841	$ 2,765

Guarantor Condensed Consolida86

Guarantor Condensed Consolidating Financial Information - Statements of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Cash (used for) provided by operating activities	$ 36	$ (238)
Investing activities
Purchases of property, plant and equipment	(89)	(137)
Proceeds from sales of assets and business	140	8
Foreign exchange contract settlements	(1)	0
Investment in affiliates	0	(30)
Intercompany investing activities	0
Cash provided by (used for) investing activities	50	(159)
Financing activities
Intercompany short-term borrowings, net	0
Debt repayments	(9)	0
Dividends paid	(5)	0
Debt issuance costs	(2)	0
Net transfers from DuPont	0	397
Cash (used for) provided by financing activities	(16)	397
Effect of exchange rate changes on cash	(1)	0
Increase in cash	69	0
Cash at beginning of period	366	0
Cash at end of period	435	0
Eliminations and Adjustments [Member]
Operating activities
Cash (used for) provided by operating activities	0	5
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and business	0	0
Foreign exchange contract settlements	0
Investment in affiliates		0
Intercompany investing activities	28
Cash provided by (used for) investing activities	28	0
Financing activities
Intercompany short-term borrowings, net	(28)
Debt repayments	0
Dividends paid	0
Debt issuance costs	0
Net transfers from DuPont		(5)
Cash (used for) provided by financing activities	(28)	(5)
Effect of exchange rate changes on cash	0	0
Increase in cash	0	0
Cash at beginning of period	0	0
Cash at end of period	0	0
Parent Company [Member]
Operating activities
Cash (used for) provided by operating activities	(17)	0
Investing activities
Purchases of property, plant and equipment	0	0
Proceeds from sales of assets and business	0	0
Foreign exchange contract settlements	0
Investment in affiliates		0
Intercompany investing activities	0
Cash provided by (used for) investing activities	0	0
Financing activities
Intercompany short-term borrowings, net	28
Debt repayments	(4)
Dividends paid	(5)
Debt issuance costs	(2)
Net transfers from DuPont		0
Cash (used for) provided by financing activities	17	0
Effect of exchange rate changes on cash	0	0
Increase in cash	0	0
Cash at beginning of period	0	0
Cash at end of period	0	0
Guarantor Subsidiaries [Member]
Operating activities
Cash (used for) provided by operating activities	21	(124)
Investing activities
Purchases of property, plant and equipment	(47)	(85)
Proceeds from sales of assets and business	140	6
Foreign exchange contract settlements	(1)
Investment in affiliates		0
Intercompany investing activities	(28)
Cash provided by (used for) investing activities	64	(79)
Financing activities
Intercompany short-term borrowings, net	0
Debt repayments	(5)
Dividends paid	0
Debt issuance costs	0
Net transfers from DuPont		203
Cash (used for) provided by financing activities	(5)	203
Effect of exchange rate changes on cash	0	0
Increase in cash	80	0
Cash at beginning of period	95	0
Cash at end of period	175	0
Non-Guarantor Subsidiaries [Member]
Operating activities
Cash (used for) provided by operating activities	32	(119)
Investing activities
Purchases of property, plant and equipment	(42)	(52)
Proceeds from sales of assets and business	0	2
Foreign exchange contract settlements	0
Investment in affiliates		(30)
Intercompany investing activities	0
Cash provided by (used for) investing activities	(42)	(80)
Financing activities
Intercompany short-term borrowings, net	0
Debt repayments	0
Dividends paid	0
Debt issuance costs	0
Net transfers from DuPont		199
Cash (used for) provided by financing activities	0	199
Effect of exchange rate changes on cash	(1)	0
Increase in cash	(11)	0
Cash at beginning of period	271	0
Cash at end of period	$ 260	$ 0